The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cardiac biomarkers market was valued at US$ 9.0 Billion in 2021.
We expect the global cardiac biomarkers market to exhibit a CAGR of 8.5% during 2022-2027.
The rising number of patients suffering from ACS due to shifting dietary patterns, coupled with the
increasing consumer awareness towards early diagnosis and treatment of cardiovascular diseases, is
currently driving the global cardiac biomarkers market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of several elective
surgeries pertaining to cardiac diseases to mitigate the risk of coronavirus infection upon hospital
Based on the location of testing, the global cardiac biomarkers market has been classified into
laboratory testing and point of care testing. Currently, laboratory testing holds largest market share.
Based on the application, the global cardiac biomarkers market can be bifurcated into myocardial
infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Among
these, myocardial infarction accounts for the majority of the total market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle
East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global cardiac biomarkers market include Abbott Laboratories,
Alere Inc., Beckman Coulter, Becton, Dickinson and Co., Biomerieux, Bio-Rad Laboratories, Randox
Laboratories, Roche Diagnostics Corporation, Siemens Healthcare, and Thermo Fisher Scientific.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at